Inotersen

Drug Profile

Inotersen

Alternative Names: IONIS TTRRx; ISIS 420915; ISIS-GSK1Rx; ISIS-TTRRx

Latest Information Update: 19 Aug 2016

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer GlaxoSmithKline; Indiana University School of Medicine; Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Amyloid polyneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Amyloid polyneuropathy
  • Phase II Amyloidosis; Cardiomyopathies

Most Recent Events

  • 09 Aug 2016 Brigham and Women's Hospital, GlaxoSmithKline and Ionis Pharmaceuticals withdraw a phase II trial in Senile systemic amyloidosis and Cardiomyopathy prior to enrolment in USA (NCT02627820)
  • 07 Jul 2016 Interim pharmacodynamics and adverse events data from a phase II trial in Amyloidosis and cardiomyopathy released by Ionis Pharmaceuticals
  • 26 May 2016 Ionis plans a phase III trial for Amyloidosis and Cardiomyopathy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top